FDA approves drug that Trump due to suggest as autism treatment
FILE PHOTO: Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly/File Photo
(In Sept 22 story, corrects paragraph one to folinic acid from folic acid)
(Reuters) -The U.S. Food and Drug Administration announced approval of leucovorin, or folinic acid, that U.S. President Donald Trump was slated to suggest as a treatment for autism symptoms at a White House event on Monday.
The FDA published a notice in the Federal Register.
GSK previously manufactured leucovorin and sold it under the name Wellcovorin. The company withdrew the drug from the market, but not for reasons of safety or effectiveness.
The Federal Register notice cited "patient-level data on over 40 patients, including both adults and pediatric patients" to support the finding that the drug can improve symptoms from cerebral folate deficiency (CFD).
According to the Federal Register entry, CFD has been reported in patients with neuropsychiatric symptoms, including autistic features.
(Reporting by Michael Erman in New Jersey and Ryan Patrick Jones in Toronto; Editing by Caitlin Webber and Cynthia Osterman)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Russian nuclear head says Ukraine attacked fuel trucks, endangered Zaporizhzhia plant
- Philippine ferry fire victims may take months to identify, authorities say
- South Korea's expanded espionage law takes effect amid push to protect chip technology
Create E-mail Alert Related Categories
ReutersRelated Entities
Donald J. Trump, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share